Lab-Grown stem cells could speed immune recovery in blood cancer transplants

NCT ID NCT03399773

Ongoing Disease control Sponsor: Fred Hutchinson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This phase 2 trial tests whether adding lab-grown umbilical cord blood cells (dilanubicel) to a standard cord blood transplant helps people with blood cancers like leukemia recover their blood and immune cells faster. Participants receive chemotherapy and radiation to prepare their body, then the transplant. The goal is to see if this approach reduces infections and other complications after transplant.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dilanubicel (lab-grown umbilical cord blood stem cells)
What this could lead to: If it works, this approach could help patients with blood cancer recover their immune system faster after a cord blood transplant, reducing infections and complications.
What could go wrong: This is an early-phase pilot study with a small number of participants. The treatment involves strong chemotherapy and radiation, which carry serious risks like infection, organ damage, and graft-versus-host disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE BIPHENOTYPIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute biphenotypic leukemia acute leukemia of ambiguous lineage acute lymphoblastic leukemia acute myeloid leukemia acute myeloid leukemia, MLL gene rearrangement chronic myelogenous leukemia, BCR-ABL1 positive hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm Leukemia, Myelogenous, Chronic, BCR-ABL Positive myelodysplastic syndrome myelodysplastic syndrome with excess blasts Myelodysplastic Syndromes Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE BIPHENOTYPIC LEUKEMIA ACUTE LYMPHOBLASTIC LEUKEMIA CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM MYELODYSPLASTIC SYNDROME MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS

Contacts and locations

Show contact details

Locations

Fred Hutch/University of Washington Cancer Consortium

Seattle, Washington, 98109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.